B
DTIL icon

Bailard’s Precision BioSciences DTIL Stock Holding History

Bailard’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-340
Closed -$85K – 577
2020
Q2 		$85K Sell
340
-7,610
-96% -$1.67M ﹤0.01% 489
2020
Q1 		$1.44M Buy
7,950
+3,167
+66% +$829K 0.1% 148
2019
Q4 		$1.99M Buy
+4,783
New +$1.5M 0.11% 153

Other funds holding DTIL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WHAM
Windmill Hill Asset Management Waddesdon, United Kingdom $321M AUM 25.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bailard's DTIL Position: Q3 2020 in Review

Bailard sold out of Precision BioSciences (DTIL) in Q3 2020, closing a stake of 340 shares — an estimated $85K sold.

Bailard first reported a position in DTIL in Q4 2019 and held it in 3 quarters. The position peaked at $1.99M in Q4 2019. 116 funds tracked by Wall St. Rank hold DTIL as of Q3 2020.

  • Bailard reported no remaining Precision BioSciences position as of Q3 2020 after selling out during the quarter.
  • Bailard sold 340 Precision BioSciences shares in Q3 2020, an estimated $85K.
  • Bailard first reported a position in Precision BioSciences in Q4 2019 and held it in 3 quarters.
  • Bailard's Precision BioSciences position peaked at $1.99M in Q4 2019.
  • 116 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2020.

Based on Bailard's 13F filing for Q3 2020, filed 10 Nov 2020.